AR081540A1 - Proceso para proveer particulas con cargas electroestaticas reducidas - Google Patents

Proceso para proveer particulas con cargas electroestaticas reducidas

Info

Publication number
AR081540A1
AR081540A1 ARP110101370A ARP110101370A AR081540A1 AR 081540 A1 AR081540 A1 AR 081540A1 AR P110101370 A ARP110101370 A AR P110101370A AR P110101370 A ARP110101370 A AR P110101370A AR 081540 A1 AR081540 A1 AR 081540A1
Authority
AR
Argentina
Prior art keywords
bromide
group
process according
active ingredient
static charges
Prior art date
Application number
ARP110101370A
Other languages
English (en)
Inventor
Daniela Cocconi
Rossella Musa
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081540(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR081540A1 publication Critical patent/AR081540A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Proceso para preparar partículas vehículo para formulaciones de polvo seco para inhalación que tienen cargas electrostáticas reducidas y las partículas vehículo de las mismas.Reivindicación 7: El proceso de acuerdo con la reivindicación 6, caracterizado porque el principio activo es un agonista del receptor adrenérgico b2 seleccionado del grupo que consiste de salbutamol, terbutalina, fenoterol, salmeterol, formoterol, indacaterol, vilanterol, y milveterol. Reivindicación 8: El proceso de acuerdo con la reivindicación 6, caracterizado porque el principio activo es un corticoesteroide seleccionado del grupo que consiste de budesonida, fluticasona propionato, fluticasona furoato, mometasona furoato, beclometasona dipropionato y ciclesonida. Reivindicación 9: El proceso de acuerdo con la reivindicación 6, caracterizado porque el principio activo es un broncodilatador anticolinérgico seleccionado del grupo que consiste de, bromuro de ipratropio, bromuro de tiotropio, bromuro de oxitropio, y bromuro de glicopirronio.
ARP110101370A 2010-04-21 2011-04-20 Proceso para proveer particulas con cargas electroestaticas reducidas AR081540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10160565 2010-04-21

Publications (1)

Publication Number Publication Date
AR081540A1 true AR081540A1 (es) 2012-10-03

Family

ID=42710544

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101370A AR081540A1 (es) 2010-04-21 2011-04-20 Proceso para proveer particulas con cargas electroestaticas reducidas

Country Status (26)

Country Link
US (3) US20110262543A1 (es)
EP (1) EP2560611B1 (es)
JP (1) JP5913289B2 (es)
KR (2) KR101863523B1 (es)
CN (1) CN102858320B (es)
AR (1) AR081540A1 (es)
AU (1) AU2011244384B2 (es)
BR (1) BR112012026804B1 (es)
CA (1) CA2796934C (es)
DK (1) DK2560611T3 (es)
ES (1) ES2658179T3 (es)
HK (1) HK1174570A1 (es)
HR (1) HRP20180488T1 (es)
HU (1) HUE038555T2 (es)
IL (1) IL222519B (es)
MX (1) MX2012012045A (es)
MY (1) MY163011A (es)
NO (1) NO2560611T3 (es)
PL (1) PL2560611T3 (es)
PT (1) PT2560611T (es)
RU (1) RU2580312C2 (es)
SG (1) SG184964A1 (es)
SI (1) SI2560611T1 (es)
TW (1) TWI530301B (es)
UA (1) UA111470C2 (es)
WO (1) WO2011131663A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827045A1 (en) * 2011-02-17 2012-08-23 Cipla Limited Compositions of glycopyrrolate and a beta2-agonist
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013109208A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprising formoterol as active agent
WO2013109211A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
WO2013109209A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising fluticasone
NZ627837A (en) * 2012-01-25 2016-04-29 Chiesi Farma Spa Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
GB201205632D0 (en) * 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
SI3019153T1 (sl) * 2013-07-11 2018-12-31 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
ES2789365T3 (es) 2015-11-16 2020-10-26 Chiesi Farm Spa Un procedimiento para la preparación de una formulación de polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico
CN105891616B (zh) * 2016-06-15 2018-06-15 北京航空航天大学 一种研究带电颗粒与火焰相互作用的实验装置
WO2018018669A1 (en) * 2016-07-28 2018-02-01 Esd Technology Consulting & Licensing Co., Ltd. Static charge reduction system
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
BR112022004970A2 (pt) 2019-09-24 2022-08-23 Chiesi Farm Spa Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
KR20230066364A (ko) 2020-08-14 2023-05-15 노턴 (워터포드) 리미티드 플루티카손 프로피오네이트 및 알부테롤 술페이트의 흡입가능 제제
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas blancharjq
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
DK1393721T3 (da) * 1997-03-20 2009-03-30 Schering Corp Doseringsform af pulveragglomerater
PT1283036E (pt) 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DK1296651T3 (da) * 2000-06-27 2008-02-11 Vectura Ltd Fremgangsmåde til fremstilling af partikler til anvendelse i et farmaceutisk præparat
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
SI1386630T1 (sl) 2002-07-31 2006-10-31 Chiesi Farma Spa Inhalator za prasek
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
RU2006141358A (ru) * 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
EP2044023B1 (en) 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
US20190216731A1 (en) 2019-07-18
AU2011244384B2 (en) 2016-06-23
BR112012026804A2 (pt) 2016-07-12
TW201206498A (en) 2012-02-16
KR20170118975A (ko) 2017-10-25
AU2011244384A1 (en) 2012-11-15
HRP20180488T1 (hr) 2018-07-13
EP2560611A1 (en) 2013-02-27
DK2560611T3 (en) 2018-02-26
PL2560611T3 (pl) 2018-05-30
JP2013525327A (ja) 2013-06-20
PT2560611T (pt) 2018-02-07
TWI530301B (zh) 2016-04-21
WO2011131663A1 (en) 2011-10-27
CA2796934C (en) 2018-11-20
JP5913289B2 (ja) 2016-04-27
HUE038555T2 (hu) 2018-10-29
SG184964A1 (en) 2012-11-29
IL222519A0 (en) 2012-12-31
RU2580312C2 (ru) 2016-04-10
CA2796934A1 (en) 2011-10-27
CN102858320A (zh) 2013-01-02
EP2560611B1 (en) 2018-01-03
NO2560611T3 (es) 2018-06-02
HK1174570A1 (en) 2013-06-14
MY163011A (en) 2017-07-31
BR112012026804B1 (pt) 2021-11-16
UA111470C2 (uk) 2016-05-10
SI2560611T1 (en) 2018-03-30
RU2012145762A (ru) 2014-05-27
US20230364015A1 (en) 2023-11-16
MX2012012045A (es) 2012-12-17
US20110262543A1 (en) 2011-10-27
KR20130062268A (ko) 2013-06-12
ES2658179T3 (es) 2018-03-08
CN102858320B (zh) 2014-10-29
IL222519B (en) 2018-03-29
KR101863523B1 (ko) 2018-05-31

Similar Documents

Publication Publication Date Title
AR081540A1 (es) Proceso para proveer particulas con cargas electroestaticas reducidas
HRP20201711T1 (hr) Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida
MA39155A1 (fr) Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
HRP20180944T1 (hr) Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
RU2012142295A (ru) Способ приготовления частиц носителя для сухих порошков для ингаляции
NZ629920A (en) A method for making an inhalable pharmaceutical composition using a resonant acoustic blender
RU2012138909A (ru) Фармацевтическая порошковая композиция для ингаляций
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
NZ600789A (en) Aerosol formulation for copd
HRP20200537T1 (hr) Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
PH12014502746B1 (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
AR102305A1 (es) Procedimiento para preparar formulación farmacéutica inhalable de polvo seco
JP2014527056A5 (es)
JP2013519413A5 (es)
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
BR112014003907A2 (pt) método para preparar inalador pulverizado de dose medida para tratar doença respiratória
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
AR098867A1 (es) Composición farmacéutica en polvo seco para inhalación
TR201714893A1 (tr) Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi.
MX2017004583A (es) Composicion farmaceutica que contiene budesonida y formoterol.

Legal Events

Date Code Title Description
FC Refusal